Apretude is a long-acting injectable medication used for HIV pre-exposure prophylaxis (PrEP). Planned Parenthood will offer ...

Mathematical models indicate that the worst-case scenario of the Trump administration’s HIV-related cuts could result in 3 ...

The Trump administration has lifted a freeze on federal funds for HIV prevention and surveillance programs, officials said, ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

The 'Silence=Death' poster from the early years of the AIDS crisis holds true today with the possibility of federal cuts to ...

State's Health Outreach and Prevention program will end June 30 after federal funding cuts to HIV outreach and prevention ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...

A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV.